RARE · Ultragenyx Pharmaceutical Inc.
AI read · Neutral
The AI's read
FDA granted accelerated approval to Genglycos, Ultragenyx’s first gene therapy and the first FDA‑approved treatment for GSDIa. That turns a tiny, previously untreatable patient pool into a clear commercial path. The market has already cheered with an ~8.7% premarket pop, but RARE’s RSI is 30.53, so the move isn’t obviously stretched. Analysts flag a $2.7M wholesale acquisition cost and model ~$362M peak sales, which implies real upside versus a 1,500–2,500 U.S. patient base. We lean bullish. Approval plus high per-patient pricing and a 10‑year monitoring commitment create durable optionality, but expect volatile, binary news flow and tighten sizing accordingly.